Adeniyi, A. A., Brindley, G. S., Pryor, J. P., and Ralph, D. J. Yohimbine in the treatment of orgasmic dysfunction. Asian J Androl 2007;9(3):403-407. View abstract.
Albus, M., Zahn, T. P., and Breier, A. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur.Arch.Psychiatry Clin.Neurosci. 1992;241(6):337-344. View abstract.
Albus, M., Zahn, T. P., and Breier, A. Anxiogenic properties of yohimbine. II. Influence of experimental set and setting. Eur Arch Psychiatry Clin Neurosci. 1992;241(6):345-351. View abstract.
Bagheri, H., Schmitt, L., Berlan, M., and Montastruc, J. L. Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants. Br J Clin Pharmacol 1992;34(6):555-558. View abstract.
Berlin, I., Crespo-Laumonnier, B., Cournot, A., Landault, C., Aubin, F., Legrand, J. C., and Puech, A. J. The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol.Ther. 1991;49(4):362-369. View abstract.
Boon, N. A., Elliott, J. M., Grahame-Smith, D. G., John-Green, T., and Stump, K. A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]- dihydroergocryptine. J Auton.Pharmacol 1983;3(2):89-95. View abstract.
Bourin, M., Malinge, M., and Guitton, B. Provocative agents in panic disorder. Therapie 1995;50(4):301-306. View abstract.
Braddock, L., Cowen, P. J., Elliott, J. M., Fraser, S., and Stump, K. Binding of yohimbine and imipramine to platelets in depressive illness. Psychol.Med 1986;16(4):765-773. View abstract.
Bremner, J. D., Innis, R. B., Ng, C. K., Staib, L. H., Salomon, R. M., Bronen, R. A., Duncan, J., Southwick, S. M., Krystal, J. H., Rich, D., Zubal, G., Dey, H., Soufer, R., and Charney, D. S. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch.Gen.Psychiatry 1997;54(3):246-254. View abstract.
Charney, D. S., Heninger, G. R., and Sternberg, D. E. Assessment of alpha 2 adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci 6-7-1982;30(23):2033-2041. View abstract.
Giampreti, A., Lonati, D., Locatelli, C., Rocchi, L., and Campailla, M. T. Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol.(Phila) 2009;47(8):827-829. View abstract.
Gurguis, G. N., Vitton, B. J., and Uhde, T. W. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res. 6-16-1997;71(1):27-39. View abstract.
Landis, E. and Shore, E. Yohimbine-induced bronchospasm. Chest 1989;96(6):1424. View abstract.
Mann, K., Klingler, T., Noe, S., Roschke, J., Muller, S., and Benkert, O. Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Arch.Sex Behav. 1996;25(1):1-16. View abstract.
Morgan, C. A., III, Grillon, C., Southwick, S. M., Nagy, L. M., Davis, M., Krystal, J. H., and Charney, D. S. Yohimbine facilitated acoustic startle in combat veterans with post- traumatic stress disorder. Psychopharmacology (Berl) 1995;117(4):466-471. View abstract.
Mustonen, P., Savola, J., and Lassila, R. Atipamezole, an imidazoline-type alpha(2)-adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine. Thromb.Res 8-1-2000;99(3):231-237. View abstract.
Myers, A. and Barrueto, F., Jr. Refractory priapism associated with ingestion of yohimbe extract. J Med Toxicol. 2009;5(4):223-225. View abstract.
Rasmusson, A. M., Hauger, R. L., Morgan, C. A., Bremner, J. D., Charney, D. S., and Southwick, S. M. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol.Psychiatry 3-15-2000;47(6):526-539. View abstract.
Riley AJ, Goodman R, Kellett JM, and et al. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual Marital Ther 1989;4(1):17-26.
Rowland, D. L., Kallan, K., and Slob, A. K. Yohimbine, erectile capacity, and sexual response in men. Arch Sex Behav 1997;26(1):49-62. View abstract.
Siddiqui, M. A., More-O'Ferrall, D., Hammod, R. S., Baime, R. V., and Staddon, A. P. Agranulocytosis associated with yohimbine use. Arch.Intern.Med 6-10-1996;156(11):1235-1237. View abstract.
Southwick, S. M., Krystal, J. H., Bremner, J. D., Morgan, C. A., III, Nicolaou, A. L., Nagy, L. M., Johnson, D. R., Heninger, G. R., and Charney, D. S. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch.Gen.Psychiatry 1997;54(8):749-758. View abstract.
Susset, J. G., Tessier, C. D., Wincze, J., Bansal, S., Malhotra, C., and Schwacha, M. G. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989;141(6):1360-1363. View abstract.
Swann, A. C. Mechanisms of impulsivity in bipolar disorder and related illness. Epidemiol.Psichiatr.Soc. 2010;19(2):120-130. View abstract.
Swann, A. C., Birnbaum, D., Jagar, A. A., Dougherty, D. M., and Moeller, F. G. Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol.Psychiatry 5-15-2005;57(10):1209-1211. View abstract.
Amato RJ, Hulin MW, Winsauer PJ. A comparison of dehydroepiandrosterone and 7-keto dehydroepiandrosterone with other drugs that modulate ethanol intake in rats responding under a multiple schedule. Behav Pharmacol 2012;23(3):250-61. View abstract.
Arthur JM, Casañas SJ, Raymond JR. Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Biochem Pharmacol. 1993;45(11):2337-41. View abstract.
Aziz TA, Hussain SA, Mahwi TO, Ahmed ZA, Rahman HS, Rasedee A. The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial. Drug Des Devel Ther. 2018;12:735-742. View abstract.
Bernauer W. Antiarrhythmic and antinecrotic effects of yohimbine stereoisomers in rats during coronary occlusion and reperfusion. Basic Res Cardiol. 1990;85(2):132-41. View abstract.
Beyer CE, Lin Q, Rosenzweig-Lipson S, Schechter LE. Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine. Eur J Pharmacol. 2006;539(3):164-7. View abstract.
Callahan MF, Beales M, Oltmans GA. Yohimbine and rauwolscine reduce food intake of genetically obese (obob) and lean mice. Pharmacol Biochem Behav. 1984;20(4):591-9. View abstract.
Cheung YD, Barnett DB, Nahorski SR. [3H]Rauwolscine and [3H]yohimbine binding to rat cerebral and human platelet membranes: possible heterogeneity of alpha 2-adrenoceptors. Eur J Pharmacol. 1982;84(1-2):79-85. View abstract.
Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Test Anal. 2015 Sep 22. View abstract.
De Vos H, Czerwiec E, De Backer JP, De Potter W, Vauquelin G. [3H]rauwolscine behaves as an agonist for the 5-HT1A receptors in human frontal cortex membranes. Eur J Pharmacol. 1991;207(1):1-8. View abstract.
Doxey JC, Lane AC, Roach AG, Virdee NK. Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch Pharmacol. 1984;325(2):136-44. View abstract.
Foster S, Tyler VE. Tyler's Honest Herbal, 4th ed., Binghamton, NY: Haworth Herbal Press, 1999.
Godfraind T, Miller RC, Socrates Lima J. Effects of yohimbine, rauwolscine and corynanthine on contractions and calcium fluxes induced by depolarization and prostaglandin F2 alpha in rat aorta. Br J Pharmacol. 1983;80(1):115-21. View abstract.
Health Canada. Five unauthorized products seized from Keebo Sports Supplements in Winnipeg may pose serious health risks. September 30 2016. Available at: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/60456a-eng.php.
Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992;53:207-9. View abstract.
Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-22. View abstract.
Kaumann AJ. Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1983;323(2):149-54. View abstract.
Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann Pharmacother 2010;44:1022-9. View abstract.
Milman N, Scheibel J, Jessen O. Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study. Acta Derm Venereol 1980;60:85-7. View abstract.
Norman TR, Kimber NM, Judd FK, Burrows GD, McIntyre IM. Platelet 3H-rauwolscine binding in patients with panic attacks. Psychiatry Res. 1987;22(1):43-8. View abstract.
Palij P, Stamford JA. Rauwolscine potentiates the effect of desipramine on limbic noradrenaline efflux. Neuroreport. 1996;7(6):1121-4. View abstract.
Pimoule C, Briley MS, Gay C, et al. 3H-Rauwolscine binding in platelets from depressed patients and healthy volunteers. Psychopharmacology (Berl). 1983;79(4):308-12. View abstract.
Ruck B, Shih RD, Marcus SM. Hypertensive crisis from herbal treatment of impotence. Am J Emerg Med. 1999;17:317-318.
Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urol 1993;41:343-5. View abstract.
Shepperson NB, Duval N, Massingham R, Langer SZ. Pre- and postsynaptic alpha adrenoceptor selectivity studies with yohimbine and its two diastereoisomers rauwolscine and corynanthine in the anesthetized dog. J Pharmacol Exp Ther. 1981;219(2):540-6. View abstract.
Southwick SM, Morgan CA III, Charney DS, High JR. Yohimbine use in a natural setting: effects on post-traumatic stress disorder. Biol Psychiatr 1999;46:442-4. View abstract.
Szabo B, Hedler L, Starke K. Peripheral presynaptic and central effects of clonidine, yohimbine and rauwolscine on the sympathetic nervous system in rabbits. Naunyn Schmiedebergs Arch Pharmacol. 1989;340(6):648-57. View abstract.
Tabrizchi R, Pang CC. Comparative effects of rauwolscine, prazosin, and phentolamine on blood pressure and cardiac output in anesthetized rats. Can J Physiol Pharmacol. 1987;65(7):1421-7. View abstract.
Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998;159:122-4. View abstract.
VandenBrink, B. M., Foti, R. S., Rock, D. A., Wienkers, L. C., and Wahlstrom, J. L. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos. 2012;40(1):47-53. View abstract.
Villazón M, Enguix MJ, Tristán H, et al. Different pharmacological properties of two equipotent antagonists (clozapine and rauwolscine) for 5-HT2B receptors in rat stomach fundus. Biochem Pharmacol. 2003;66(6):927-37. View abstract.
Wylie KR. Yohimbine and sinusitis. Br J Psychiatry. 1996;169(3):384-5. View abstract.
Yu J, Ma Y, Drisko J, Chen Q. Antitumor activities of Rauwolfia vomitoria extract and potentiation of carboplatin effects against ovarian cancer. Curr Ther Res Clin Exp 2013;75:8-14. View abstract.